

Product datasheet for **TA364470S**


GRO gamma (CXCL3) Rabbit Polyclonal Antibody

Product data:


Product Type:	Primary Antibodies
Applications:	IHC
Recommended Dilution:	IHC: 25-100 Positive control: Human liver cancer Predicted cell location: Cytoplasm
Reactivity:	Human
Host:	Rabbit
Isotype:	IgG
Clonality:	Polyclonal
Immunogen:	Fusion protein of human CXCL3
Formulation:	pH7.4 PBS, 0.05% NaN ₃ , 40% Glycerol
Purification:	Antigen affinity purification
Conjugation:	Unconjugated
Storage:	Store at -20°C.
Stability:	1 year
Gene Name:	C-X-C motif chemokine ligand 3
Database Link:	Entrez Gene 2921 Human P19876
Background:	Chemokine (C-X-C motif) ligand 3 (CXCL3) is a small cytokine belonging to the CXC chemokine family that is also known as GRO3 oncogene (GRO3), GRO protein gamma (GROγ) and macrophage inflammatory protein-2-beta (MIP2β). CXCL3 controls migration and adhesion of monocytes and mediates its effects on its target cell by interacting with a cell surface chemokine receptor called CXCR2. More recently, it has been shown that Cxcl3 regulates cell autonomously the migration of the precursors of cerebellar granule neurons toward the internal layers of cerebellum, during the morphogenesis of cerebellum.
Synonyms:	CINC-2b; GRO-gamma; GRO-gamma(1-73); GRO3; GROG; MIP-2b; MIP2-beta; MIP2B; SCYB3




[View online »](#)

Product images:


Immunohistochemistry of paraffin-embedded Human liver cancer tissue using [TA364470] (CXCL3 Antibody) at dilution 1/20 (Original magnification: $\times 200$)



Immunohistochemistry of paraffin-embedded Human liver cancer tissue using [TA364470] (CXCL3 Antibody) at dilution 1/20, treated with fusion protein. (Original magnification: $\times 200$)



Immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using [TA364470] (CXCL3 Antibody) at dilution 1/20 (Original magnification: ×200)



Immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using [TA364470] (CXCL3 Antibody) at dilution 1/20, treated with fusion protein. (Original magnification: ×200)